Simulations Plus

“The integration of our industry-leading ADMET Predictor and GastroPlus® mechanistic PBPK simulations into the initial generative chemical design process is what sets us apart from other machine learning drug design companies,” says AIDD Principal Scientist and former City of Hope Professor Jeremy Jones. “Our platform offers everything a medicinal chemist would want, at incredible speed.”

Simulations Plus is excited to announce that we are the recipients of a Comparably Award for “Best Company for Women” in 2022.

Merry Christmas and Happy Holidays!

With more than 20 years of industry experience, Chief Science Officer of DILIsym Services, Scott Q. Siler describes it this way, “think of modeling like photography.”

Breaking News! The new version of GP (version 9.8.3) is now available for download.

As the summer season heats up here in New England, we invite you all to join us in honoring 2022 World Lung Cancer Day.

An estimated 236,740 people in the U.S. will be diagnosed with lung cancer in 2022. That’s 649 people each day, 27 people each hour, and one person every 2½ minutes.

Oncology drugs have historically followed the dosing strategy that “more is better” until the maximum tolerated dose (MTD) is reached.

Hard to believe that we’re already in the middle of summer.

An update from Dr. Paul B. Watkins on the comparison of lixivaptan’s liver safety profile

Hello again GastroPlus scientists, Simulations Plus is a great place to work.